Table 1.
Effects of simvastatin and rapamycin on TSC2-null tumor volume
| Experimental conditions (no. of animals) | Tumor volume ± SE (mm3) at day: |
||||
|---|---|---|---|---|---|
| 0 | 10 | 22 | 31 | 41 | |
| 1. Control (20) | 56.1 ± 8.6 | 141.2 ± 18.5 | 159.7 ± 34.4 | 232.0 ± 81 | 201.0 ± 71 |
| 2. Rapamycin (27) | 61.5 ± 9.4 | 71.8 ± 25.2a | 46.5 ± 18.4a | 43.3 ± 12.5a | 57.7 ± 43.1a |
| 3. Simvastatin (25) | 57 ± 4.4 | 128 ± 32.8 | 64.5 ± 23.8a | 41.8 ± 15a | 53.1 ± 21.3a |
| 4. Rapamycin plus simvastatin (18) | 56.8 ± 3.4 | 46 ± 4.0b | 48.9 ± 16.9a | 10.2 ± 3.6c | 3.6 ± 1.9b |
a
P < 0.05 for rapamycin and/or simvastatin versus control by ANOVA (Bonferroni-Dunn).
b
P < 0.01 for rapamycin plus simvastatin (day 10) versus simvastatin (day 10); for rapamycin plus simvastatin (day 41) versus rapamycin (day 41); and for rapamycin plus simvastatin (day 41) versus simvastatin (day 41) by ANOVA (Bonferroni-Dunn).
c
P < 0.05 for rapamycin plus simvastatin (day 31) versus rapamycin (day 31) and for rapamycin plus simvastatin (day 31) versus simvastatin (day 31) by ANOVA (Bonferroni-Dunn).